Introduction
Estimation of BCR-ABL mRNA levels is an important indicator of therapeutic response for patients with chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia, but there is substantial variation in the real time quantitative PCR (RQ-PCR) methodology employed, what control gene is used for normalisation and how results are reported An international scale (IS) has recently been established that is anchored to two key points defined in the IRIS trial: a common baseline (100% BCR-ABL IS ) and major molecular response (0.1% BCR-ABL IS )
To help propagate and improve the accessibility of the IS we sought to develop internationally accredited BCR-ABL reference reagents. 3ml glass ampoules were filled with 1.5 x 10 6 cells (0.5ml) for freeze drying and approximately 3500 vials of each material were produced
Field trial evaluation of the reagents was performed by 10 laboratories with stable and validated conversion factors (6 European Union, 1 Canada, 3 Asia/Australasia) RNA was extracted from each material and, following reverse transcription, cDNA was tested in lab specific qPCR assays.
Transcript copy numbers for BCR-ABL and the three control genes were used to calculate %BCR-ABL/ABL, %BCR-ABL/BCR and %BCR-ABL/GUSB.
The mean % values for each material were then converted to the IS by multiplying the %BCR-ABL/control gene value by the established CF for each laboratory. 
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